Latest News and Events

February 2019

Nanomerics announces new US and Japan patents

Nanomerics is pleased to announce the imminent publication of key patents underpinning its NM127 asset. Nanomerics has been notified by the US Patent and Trademark Office of the imminent publication of US10213474 on the 26th of February.  This key patent further strengthens Nanomerics patent portfolio and enables Nanomerics to continue the development of NM127.  Nanomerics is also pleased to announce a notice of allowance issued by the Japanese Intellectual Property Office for application JP2016-526933.

December 2018

Nanomerics wins Innovate UK grant to progress development of NM127 pain therapeutic

Today Nanomerics announced the award of a research grant from Innovate UK.  The award has been made to progress the development of NM127, Nanomerics’ pain asset.  The award will fund a collaboration between Nanomerics Ltd.  and Alchemy Pharmatech Ltd. and will involve the coupling of Alchemy Pharmatech’s Naltos nasal delivery device with Nanomerics’ enkephalin based formulation for the treatment of breakthrough, neuropathic and post operative pain.

October 2018

September 2018

Nanomerics Announces New Canadian Patent Underpinning its Enkephalin Assets Proceeding to Grant

Nanomerics today announced that the Canadian Intellectual Property Office will allow key patent application underpinning its enkephalin pain therapeutic (patent application number - CA2754140) to proceed to grant.   This patent supports Nanomerics’ pain therapeutics, including NM0127 and provides further assurances to potential partners on patent protection in key markets.  Nanomerics will continue to defend its assets with key patent applications and ongoing patent prosecution.  This is a major component of its business strategy.

August 2018

EPO logo

European Patent Office to Allow the Granting of Two Key Molecular Envelope Technology Patents

Nanomerics today announced the receipt of news that two key patents on its Molecular Envelope Technology (MET) will be granted by the European Patent Office.  

Patent applications EP07789150.5 and EP03748286.6 will be allowed to grant by the European Patent Office, thus further strengthening Nanomerics’ patent portfolio and its business activities in the European Union. These two patents directly underpin Nanomerics’ key drug delivery technology -  Nanomerics’ MET.

February 2018